Ahmed et al.

Iraqi Journal of Science, 2025, Vol. 66, No. 2, pp: 801-829 DOI: 10.24996/ijs.2025.66.2.21





ISSN: 0067-2904

Design and Implementation of a Prototype for Frailty Diseases Based on Decision Support System

Ahmed Shihab Ahmed *, Hussein Ali Salah ², Safa Bhar Layeb³

¹ Department of Basic Sciences, College of Nursing, University of Baghdad, Baghdad, IRAQ
 ² Department of Computer Systems, Technical Institute- Suwaira, Middle Technical University, Baghdad, IRAQ
 ³LR-OASIS, National Engineering School of Tunis, University of Tunis El Manar, Tunis, Tunisia

Received: 8/9/2023 Accepted: 25/2/2024 Published: 28/2/2025

Abstract

An older people's disease known as frailty occurs when an elderly individual exhibits heightened susceptibility to little stimuli. An individual who is feeble experiences limited ability to grasp, an unintended reduction in weight, a feeling of happiness, a sluggish gait, and trouble standing. The detection of frailty phenomenology is one of the greatest developments in geriatric medicine in the past 20 years. Frailty develops into an impairment if left unchecked. Clinical decision support systems are used to help professionals, or physicians, make more informed and complex decisions. Thus, in order to assist the board in providing healthcare effortlessly in controlling the frailty conditions and, usually, to identify the class of acquiring a medical condition (frailty) and offer an appropriate procedure therapy based on what can be placed to the perfect use, an appropriate support system has been set up using doctors' expertise and information mining extraction structure. In order to categorize this condition and analyze their respective efficacy and rectification rates, we suggest using the Decision Trees, C4.5, ID3, Random Forests (RF), Logistic Regression (LR), and CART algorithms. With a decrease in undertriaging elderly patients who are seriously ill, predictive machine learning assessment demonstrated superior discriminating capacity for predicting medical results and attitudes. The present research identifies an effective combination of six characteristics-unintentional reduction in weight, sluggish weak strength or tiredness, frequent chair current stands, and age-that assist in predicting death with precision and F1 score using predictive machine learning techniques. In order to obtain consistently high accuracy throughout the characteristics of frailty illness detection, numerous algorithms based on machine learning are being examined. Five cases of rigorous testing validate the excellent predictive accuracy of the suggested framework. This research would hasten the process of making decisions in healthcare organizations so that targeted therapies can be administered promptly and precisely.

Keywords: Decision tree Algorithm, Clinical Decision Support Systems, Frailty, Decision Support System, C4.5 Algorithm.

^{*}Email: ahmedshihabinfo@conursing.uobaghdad.edu.iq

³ المدرسة الوطنية للمهندسين بتونس, جامعة تونس المنار , تونس, تونسية

الخلاصة

يحدث مرض كبار السن المعروف باسم الضعف عندما يكون الفرد المسن معرضا بدرجة أكبر لقلة التحفيز. فالفرد الضعيف يختبر قدرة محدودة على الفهم ، تخفيضا غير مقصود في الوزن ، شعورا بالسعادة ، مشية بطيئة ، وصعوبة في الوقوف . وبمثل الكشف عن علم الأحياء الفينوغرافي الضعيف أحد أكبر التطورات في مجال طب الشيخوخة في السنوات العشرين الماضية. وبتطور الضعف إلى ضعف إذا ترك دون كابح. وتستعمل نظم دعم القرارات السريرية لمساعدة المهنيين أو الأطباء على اتخاذ قرارات أكثر استنارة وتعقيدا. ومن ثم، وبغية مساعدة المجلس على توفير الرعاية الصحية دون جهد في السيطرة على ظروف الضعف، وتحديد فئة الحصول على حالة صحية (الضعف) عادة، وتقديم علاج إجراءي مناسب على أساس ما يمكن وضعه للاستعمال الأمثل، أنشئ نظام دعم مناسب باستعمال الخبرة الفنية للأطباء وهيكل استخراج المعلومات من التعدين. ولكي نصنف هذه الحالة ونحلل كفاءة كل منها ومعدلات تصحيحها، نقترح استخدام خوارزميات القرار C4.5 ، وLogistical Regression (LR)، وRandom Forests (RF)، وLogistical Regression ، و ومع انخفاض نقص التغذية في المرضى المسنين المصابين بأمراض خطيرة، أظهر تقييم التعلم بالآلات التنبؤبة قدرة تمييزبة متفوقة على التنبؤ بالنتائج والمواقف الطبية. وبحدد هذا البحث مزبجاً فعالاً من ست خصائص - تخفيض غير متعمد في الوزن، وضعف بطيء في القوة أو التعب، وتواتر المقاعد الحالية للكرسى، والعمر - تساعد في التنبؤ بالوفاة بدقة، ودرجة F1 باستخدام تقنيات التعلم بالآلات التنبؤية. وبغية الحصول باستمرار على دقة عالية في جميع خصائص الكشف عن الأمراض الضعيفة، يجرى فحص العديد من الخوارزميات القائمة على التعلم الآلي. ويتثبت خمس حالات من الاختبار الدقيق الدقة التنبؤية الممتازة للإطار المقترح. ومن شأن هذا البحث أن يعجل بعملية اتخاذ القرارات في منظمات الرعاية الصحية بحيث يمكن إدارة العلاجات المستهدفة على وجه السرعة وبدقة.

1. Introduction

Frailty's significance in the clinical setting has already been discussed [1]. The Organization for World Health Organizations (WHO) recently advanced the notion of intrinsic capability in response to the scientific community's intense debate over the premise that frailty causes impairment. Fundamentally, it appears that innate capacity is the antithesis of weakness. The process of acquiring and retaining functional capacity that promotes wellbeing as people age was termed "healthy aging." According to the argument, healthy aging ultimately depends on an individual's inherent capacity and how that individual interacts with his or her surroundings [2].

Individualized strength training programs must include at least three types of exercise: aerobic, strength, and balance exercises. They must also be social, since research has shown that people are much more likely to stick with an exercise routine when they do it with other people [3].

The workout included phases for strength, aerobics, and equilibrium. The outcomes were very positive. Exercise considerably improved the health of those who participated, which improved their health status by 56%, meaning that 56% of the patients were less frail than before they began the exercise. Additionally, other parameters that are typically not reported while researching frailty were enhanced. For instance, the exercise intervention group's primary care visits decreased by 45% [4].

A widely accepted definition of frailty is still lacking among clinicians today. There is consensus, according to a review, that frailty is a step between robustness and incapacity.

Contrarily, utilizing a scale that categorizes levels of frailty, from a high-risk state to a seriously crippled state, was suggested [5, 6].

Frailty can have many different facets. Frailty mostly manifests in the physical realm, but there are other areas as well, including the psychological and social domains. According to the prominent feature, recent ideas of frailty might sometimes be expressed as physical frailty, psychological frailty, or social frailty [7, 8].

Physical fragility is regarded as a susceptible state based on a large corpus of agingrelated characteristics, while sarcopenia is a key part of biological frailty. It is also important to note that it has been suggested that there is a subtype of frailty known as cognitive frailty within psychological frailty that is accompanied by decreased cognitive performance coupled with physical frailty [9, 10].

Although gathering and analyzing medical data used to be the responsibility of health care experts, the broad accessibility of massive amounts of health data has drastically and permanently altered the nature of modern healthcare. Even patients are now beginning to gather their own health information by using tools like smart watches or apps, which may one day be a significant source of health information [11].

In order to make the best judgment possible, a significant element of medical education is devoted to learning how to separate important information from irrelevant information. The vast number, rapidity of production, complexity, and potential utility of the data that is currently accessible, however, go beyond what can be understood about frailty disease. On the other hand, advances in computing capability and data analytics offer the chance to gain fresh perspectives and instantly apply data-driven added value to clinical practice. Clinical decision support (CDS) systems fall under this category, and their broad definition is information systems meant to support clinical decision-making by integrating data from various sources of health, including electronic health records, laboratory test results, and other sources [12].

Although CDS systems have a wide range of features and functions, they all strive to produce therapeutically appropriate results based on input data. A rule or model as straightforward as an if-then rule or as complicated as a prediction model for potential incidental findings might support a choice. A CDS system's equivalent output can range from using the generated prediction as an input for a clinical decision to actually acting on the decision without human intervention. Additionally, the creation of sophisticated algorithms is starting to extend beyond the realm of imaging [13].

They will briefly discuss a number of ethical topics. However, they sincerely believe that ethical issues surrounding algorithmic decision-making merit their own study and respectfully direct the reader to a recent overview on the subject. They demonstrate in this work that a well-designed CDS system requires the data, algorithms, and decision support of health care experts who are knowledgeable in the development of frailty diseases [14].

The initial CDSS is an expanded version of the preceding expert system, and its main objective is to use machine learning to develop computer programs that mimic human thought. A group of computer algorithms known as machine learning may recognize human behavior patterns and use them to predict the future or make intelligent decisions. The details given by the doctor, staff, pharmacy, and other healthcare providers are one source of data that the machine learning algorithms heavily rely on [15].

The DSS was developed to assist physicians who frequently rely on static information that may be out-of-date. Doctors and medical facilities would benefit from a DSS that can learn

about the relationships between knowledge of the past, infections in the population, symptoms, the pathology of a disease, family history, and test results [16].

The combination of data mining with DSS can lead to the development of DSS and enable the treatment of new types of concerns that have not previously been addressed. They also say that data mining and decision support can broaden the current method and come up with new ways to deal with critical thinking by letting information from experts and information extracted from information be combined [17].

There are two primary methodologies for identifying frailty. The initial approach is the phenotypic model, which assesses frailty by utilizing the elements of the CHS [18]. The second approach is the accumulating deficits approach, which introduces the frailty indicator [19].

Phenotype refers to the deterioration of physical abilities that occurs with age, as determined by certain indicators: involuntary weight reduction, expressed fatigue, reduced strength (measured by grip strength), decreased exercise, and a slow pace of walking. Based on this model, the existence of just one or two of the previously described factors signifies a pre-frail condition; the existence of three or more factors signifies frailty; and a lack of any factors signifies robustness [18]. This framework offers a widely accepted method for evaluating physiological fragility. Nevertheless, [18]'s investigation found a lack of generally accepted standards for rating each element. Additionally, it pointed out that there are various additional requirements that depend on the identical phenotype.

The Frailty Index quantifies the ratio of accumulating deficits in the factors that contribute to overall health and autonomy. Based on the belief that these deficits indicate a degree of frailty, it is suggested that the frailty indices be created using more than 30 parameters associated with indications, routine tasks, diseases, memory loss, etc. This will ensure that the measure reflects the general characteristics of the entire organism instead of focusing on any specific useful deficiency. According to [19], it is possible to encode category, normal, and interval parameters so that 0 denotes the absence of a deficit and 1 denotes the complete description of the shortfall.

An essential finding of the present research is that the level of inherent ability generally tends to rise with age. Consequently, as individuals grow older, the disparities in inherent abilities between them will increase compared to when they were younger. While frailty is welldefined in medical terms, this particular concept has not received the same level of clarity. However, it serves to redirect focus away from public health interventions aimed at promoting health, such as immunization or systematic efforts to identify age-related issues. Unquestionably, the emerging notion of natural ability emphasizes the necessity for people to actively enhance the development of their inherent capability, particularly under the careful observation of medical experts.

This article's goal is to describe the creation of a clinical decision support system for managing frailty disease issues and to suggest symptoms, treatments, and avoidances for each level among them. In our suggested work, we've given doctors or their representatives a tool that has all the information about frailty disease so they may make the best judgment possible regarding how severe the disease is and choose the best course of action to minimize risks. DSS provides tools to assess disease severity, identify patterns, and provide immediate instructions or activities. Also, it demonstrates reasonable behavior, aids medical professionals in treating frailty diseases, and concentrates on finding information sources. The main point of this paper is to make a DSS better at using data mining algorithms (Decision Trees C4.5 algorithms, ID3 algorithms, Random Forests (RF) algorithms, Logistic Regression

(LR) algorithms, and CART algorithms) to sort people with this disease into groups and handle their requests for medical care in a way that will slowly make their frailty symptoms worse.

The following is a summary of this work's main contributions:

- Create a multi-criteria judgment based on the frailty diagnostic method's established evaluation criteria.
- Offers a new evaluation and decision-making approach based on data mining algorithms (Decision Trees algorithm, ID3 algorithm, Random Forests (RF) algorithm, Logistic Regression (LR) algorithm, C4.5 algorithm, and CART algorithm) for choosing the best frailty diagnostic method.
- Assess the suggested decision-making methodology using the five main frailty illness classification datasets.

The purpose of this paper is to present a specific clinical decision support system (DSS) that focuses on dealing with frailty evaluation. This DSS offers an analytical framework that doctors in primary care can utilize to create a thorough method for evaluating and treating older adults with multiple complicated medical issues in a straightforward and organized manner. The use of frailty assessment instruments is crucial due to the worldwide scarcity of essential evidence and knowledge regarding the well-being of elderly people. This scarcity hampers the creation and assessment of appropriate programs and regulations to address various factors and suggest signs, therapy, and preventive measures for every stage of frailty. Clinical decision-support platforms provide tools to assess the severity of infection, identify the appropriate treatment plan, and provide prompt advice or intervention. Additionally, it demonstrates the assistance a healthcare professional offers in the areas of frailty evaluation and health and aims to uncover information resources. The CDSS aims to enhance the diagnostic process and offer support to healthcare providers through the analysis and evaluation of patient information. The main goal of this paper is to improve a CDSS (Clinical Decision Support System) that is based on DTCIS (Decision Tree C4.5 Inductive Reasoning System) so that healthcare requests can be handled more smoothly. This will help slow down the progression of frailty indicators and make sure that patients are treated using the best therapy protocol. Furthermore, there are numerous proposed approaches and concepts for implementing frailty evaluation in diverse contexts. The evaluation of frailty has revealed older persons who are more susceptible to experiencing negative health consequences, such as death, impairment, declining mobility, falls, hospitalization, and death. The morphological description of frailty and the development of impairments are the most rigorously verified and widely accepted approaches for measuring frailty. A notable distinction between these two concepts of frailty lies in their understanding of the aging process and the underlying causes of frailty.

This study's primary contribution is the development of a highly effective instrument that assists researchers in studying frailty within the clinical setting. The concept of frailty as a precursor to impairment has sparked considerable contemplation among scientists. In recent years, the World Health Organization (WHO) has introduced the notion of inherent potential. Essentially, inherent capacity can be seen as the antithesis of frailty. If an individual possesses a high level of inherent ability, it is improbable that they will develop frailty. The World Health Organization (WHO) describes inherent capacity as the collective combination of a person's mental and physical capabilities that they can utilize at any given moment throughout their lifespan. Healthy aging refers to the ongoing development and preservation of functional ability that promotes happiness during the latter stages of life. The assertion posits that successful aging ultimately relies on the inherent capability of a person and the interplay between the person and their surroundings. This program is designed for novice psychiatrists working in healthcare facilities, with the aim of providing benefits to elderly individuals.

The following is how this document is set up: Address the related research on frailty diseases in Section 2. The conditions for effective CDSS installation are outlined in Section 3. The frailty assessment is described in Section 4. The results are discussed in Section 5. Conclusions are illustrated in Section 6.

2. Recent Research

The HELP framework is actually a combined data system for medical clinics with the ability to issue warnings when information irregularities in the printed copy of the infected record are present. It can either naturally produce information in the form of printed reports or it can display explicit data if that is specified. The framework also includes an event-driven component for age-specific warnings, admonitions, and reports. A clinical decision support system under trial was called Internist-I [20].

Currently, a few studies that focused on clinical determination have been taken into account. These studies used data from the user computer interface AI archive to achieve high grouping correctness's of 77% or higher by applying diverse approaches to the problem at hand [21]. Fuzzy Support Vector Clustering was used by T. Kenneth Jian Wei et al. [22] to distinguish cardiac disease. Each piece of information was relegated by this algorithm using a part-initiated measurement, and exploratory results were obtained by using a well-known benchmark of cardiac sickness. This uses nonlinear proximal assistance vector machines in a tree-based classifier.

According to synthesis analysis, F. Marta et al. [23] designed a specialized framework to analyze diabetic sickness. He has developed a framework for course learning to analyze diabetes. A fluffy-based regulator that combines expert knowledge to control blood glucose levels has been developed.

Clinicians are given recommendations based on the framework and the analytical projects on risky drug combinations. These programs can lessen issues and mistakes, prevent misunderstandings, and improve doctors' analyses. Early notification of a probable injury may affect the type of care given and its cost [24].

According to a study done in England, applying PC-based guidelines can change the way health outcomes turn out, and the unresolved questions doctors have when treating patients can provide an opportunity to use a clinical decision support system [25].

They have combined the four elements associated with successfully implementing CDSS from several studies. One was automating alerts and updates; two was making suggestions at a suitable time and place; three was making important suggestions; and four was automating the complete action. These factors have an impact on the care and handling of crisis situations. To demonstrate how quickly the DSS communicated the crisis, contextual analysis was employed. Data exchange is a crucial component for the clinical decision-support system to function properly [26].

The findings demonstrate that doctors who follow the advice of clinical decision support systems tolerate losing control over their work, losing specific skills, and losing knowledge in a situation where any non-expert can gain access to the clinical material that is chosen for the doctor. So when doctors choose to use a clinical decision support system, skilled self-sufficiency plays a big role. This study also improves two other areas: 1) the structure that encourages the chief to give a domain to doctors so they can make intuitive clinical decision support systems and share information effectively; and 2) the quality of care given to patients by using the right clinical information technology (IT) frameworks in clinics [27].

The entire CDSS must be computerized, clinical work processes must be integrated, the framework must be extensible and viable, ideal advice must be provided, costs and impacts must be evaluated, and structures must be in place before clinical decision support system administrations and modules can be shared and reused [28].

This clinical topic outlines the associations between sarcopenic patients' prognoses and outcomes and significant physical functions, falls, and mortality. First off, sarcopenia has been linked to decreased life expectancy, weakness, a higher risk of falling, and a higher risk of breaking bones after falling. According to observational research, sarcopenia raises a patient's risk of dying overall, as well as the possibility that they will have impaired physical abilities, a slower gait, or need to be hospitalized [29].

Researchers in [30] examined data from the 1,611 participant Toledo Study of Healthy Aging (mean age 75.4 years). According to the Foundation for the National Institutes of Health (FNIH) standardized criteria, 28.1% of the study population was frail, and 20.6%, 21.8%, and 28.1%, respectively, of the population had sarcopenia, according to the European Working Group on Sarcopenia in Older People (EWGSOP) definition. Frailty was prevalent in 8.2% of people with sarcopenia according to the EWGSOP, 15.7% of people with sarcopenia according to the FNIH, and 10.4% of people with sarcopenia according to the FNIH's standardized criteria. Among the frail participants, 40.3% had sarcopenia according to the EWGSOP, 72.2% had it according to the FNIH, and 65.3% had it according to the FNIH's standardized criteria. For the diagnosis of frailty, sarcopenia has a modest sensitivity (10%) but a high specificity (>97%). Sarcopenia is not a helpful biomarker of frailty, according to the study's findings, but its absence may help to rule out frailty. 32.5% of people met the criteria for frailty, while 42.5% met the criteria for pre-frailty. The study also revealed that males and females both had greater rates of sarcopenia and frailty, respectively. 42.1% of patients with sarcopenia as defined by the EWGSOP were deemed feeble based on the CHS criteria, while 25.0% were deemed frail based on the Frailty Index. According to the EWGSOP, sarcopenia was present in 36.4% of people who met the CHS frailty criteria and in 20.0% of people who met the Frailty Index criteria [31].

The researchers in [32] conducted research on Japanese ladies living in communities who were 65 years of age or older. According to the CHS criterion, they stated that 8.1% of the population was sarcopenic and that 10.6% were frail, while 56.8% were pre-frail. 50.0% of the sarcopenic participants were frail, while 37.9% of the frail participants were sarcopenic.

In a thorough review of longitudinal research [33], the researchers evaluated twenty-four studies that looked into the relationship between frailty and a higher risk of death in older people residing in the neighborhood. The researchers discovered that frailty greatly raised the chances of death, with a total risk proportion of 2.34 (95% CI 1.77-3.09) and a proportional risk of 1.83 (95% CI 1.68–1.98). In addition, the association between frailty and death was observed regardless of the specific frailty assessment tools used. These tools were classified into three categories: mental frailty devices (such as CHS standards and Brief Actual Efficiency Batteries), multifaceted devices (such as Tilburg, Netherlands Frailty Indicators), and deficits devices (such as the collected deficits models). The meta-analysis also looked at the link between frailty and different risks. It showed that being frail greatly increases the chances of being confined (1.2–1.8 times higher), established (1.7 times higher), having trouble with basic daily tasks (1.6–2.0 times higher), being unable to move around (1.5–2.6 times higher), and breaking or falling (1.2–2.8 times higher). Frailty is known to augment the probability of developing Alzheimer. [33] conducted a comprehensive examination of existing research pertaining to older individuals living in communities and performed a metaanalysis of seven investigations. A study of the research showed that being frail is a very good way to tell if someone will get Alzheimer's (risk ratio 1.28, 95% CI 1.00-1.63), cardiovascular dementia (risk ratio 2.70, 95% CI 1.40-5.23), or any kind of cognitive impairment (risk proportion 1.33, 95% CI 1.07–1.67).

In order to find out if there was a link between being frail and having bad outcomes after giving birth, [34] looked at 23 studies that included people who had heart, cancer, overall,

arterial, and broken hip surgeries. The analysis demonstrated a strong correlation between frailty and greater death rates at 30 days, 90 days, and 1 year. Additionally, frailty was found to be linked to difficulties with surgery and longer hospital stays.

A study conducted by researchers [35] involved 1,754 older individuals living in the community who did not have type 2 diabetes hyperglycemia at the beginning of the trial. The individuals were classified as frail, pre-frail, or non-frail based on the CHS standards. The people who were physically weak had a 1.87 times higher risk of developing type 2 diabetes hyperglycemia (OR 1.87, 95% CI 1.31–2.13), whereas those in the study who were at risk of becoming physically weak had a 1.60 times higher risk of developing the disease (OR 1.87, 95% CI 1.27–2.00). Furthermore, a study by [35] found that pre-frailty was autonomously linked to an increased likelihood of acquiring heart illness, while another study by [36] revealed that frailty was autonomously connected with a greater likelihood of coronary artery disease.

Polypharmacy, the utilization of many medications, is an inevitable consequence of having multiple chronic health conditions. Additionally, it serves as an indispensable indicator of unfavorable drug occurrences. According to the literature, the occurrence of negative medication effects and the presence of many health conditions can heighten the likelihood of non-frail older adults transitioning into a frail state.

A cross-sectional investigation conducted in France examined a group of individuals aged 70 years or older who lived in the neighborhood. The mean age of the participants was $83.0 \pm$ 7.5, and 59.4% of them were women. According to the CHS requirements, the investigation found that having a high number of drugs, specifically between 5 and 9, was associated with a 1.77-fold higher probability of frailty. Furthermore, having an excessive number of medicines, categorized as 10 or more, was correlated with a 4.47-fold increase in the probability of frailty. A study conducted on men ages 70 or older who live in the surrounding area revealed a correlation between the variety of medicines they take and their probability of frailty, according to the CHS requirements. Over a duration of 2 years, the probability of experiencing frailty rose 2.45 times for those taking more than five drugs (polypharmacy), with a 95% confidence interval of 1.42 to 4.23. Similarly, the probability rose 2.55 times for those taking ten or more treatments (hyperpolypharmacy), with a 95% confidence interval of 0.76 to 8.26. Similarly, a study conducted on a group of individuals aged 50 to 75 who live in the surrounding area found a clear relationship between the number of medications used and the likelihood of experiencing negative health effects. The odds ratio (OR) for having several medications (multiple drugs) was 2.30, including a 95% confidence interval (CI) of 1.60 to 3.31. The OR for having an excessive number of medications (hyperpolypharmacy) was 4.97, with a 95% CI of 2.97 to 8.32. In an 8-year further investigation sample analysis, [37] found comparable outcomes, notwithstanding the comparatively youthful age of the sample (with an average age of 60 years). During the observation duration, individuals who were prescribed between four and six drugs had a higher probability of developing frailty compared to those who were prescribed 0 to 3 prescriptions. Moreover, this probability was even greater for individuals using up to seven pharmaceuticals. These qualitative investigations offer proof that the use of many medications is a contributing factor to frailty [38].

An Australian study conducted by [39] analyzed a group of 1705 men aged \geq 70 years who lived in the neighborhood (with an average age of 76.9 + 5.5 years). Among them, 9.5% were classified as feeble. Through the receiver's operational characteristic curve examination, it was shown that a threshold of 6.5 exhibited the strongest predictive value for frailty (with a precision of 47.5%, an accuracy of 87.5%, and a region under the graph of 0.70). The longitudinal study conducted by [40] examined a group of 437 older inpatients (average age 83.0 + 6.1 years, 62.7% women) who were diagnosed as frail in roughly 52% of cases. The

study identified a threshold of 6 as the most effective value for predicting frailty, with an accuracy of 61.7%, a precision of 52.4%, and an area under the curve of 0.58. Since both research studies used the CHS criterion to identify frailty, the discrepancy in the threshold for diagnosis is likely due to variations in the group, such as variations in age, sex, and the reality that a single group consisted of community-dwelling individuals while the other included older inpatients. Regardless, the research indicates that the threshold for a certain amount of drug is estimated to be between 6 and 7 [41].

While there is a growing body of research on the results of frail older individuals, there is a lack of studies that specifically investigate medication therapies targeting frailty as a primary result. Furthermore, there is limited data available regarding the effectiveness of pharmaceuticals in preventing frailty. The study conducted by [42] investigated the correlation between frailty, sadness, and the utilization of medications for depression in a group of 27,652 women ages 65–79 who did not exhibit frailty at the beginning of the study. During a 3-year period of observation, around 15% of the subjects developed frailty. The odds ratio (OR) for frailty among antidepressant consumers who were melancholy was 3.63 (95% confidence interval [CI] 2.37–5.55), while the OR for antidepressant users who did not suffer from depression was 1.73 (95% CI 1.41–2.12). Consequently, individuals who used antidepressants were found to have a heightened susceptibility to acquiring frailty, regardless of whether or not they experienced depression. Moreover, this correlation was found to be statistically significant among those who were on antidepressants that were tricyclic, selective neurotransmitters, or various combinations of drugs for depression.

The subsequent research primarily investigated the impacts of drug utilization on elderly individuals who are in good health. While frailty was not directly used as the primary outcome, the assessed outcomes were those associated with frailty. In a group experiment comprising 3,434 elderly individuals without Alzheimer at the beginning, the researchers investigated the total usage of antagonists during the course of the investigation by considering the cumulative sum of daily dosages administered. They discovered a positive correlation between higher continuous usage and an elevated likelihood of acquiring Alzheimer (with a maximum continuous usage having a hazard ratio of 1.54). Given how common antagonistic use is among older people who are not mentally fragile, such as the use of allergy medicines, antihistamine H2-receptor inhibitors, and skeletal muscle receptor inhibitors, it makes sense to think that antagonistic use could be a strong sign of mental fragility.

The utilization of diazepam has been linked to the development of cognition and an increased risk of falls, indicating that the use of diazepam can be used as an indicator of frailty in otherwise healthy persons. In a group study, researchers discovered that individuals who initiated benzodiazepine therapy had a considerably higher likelihood of developing dementia during a 15-year monitoring phase. The hazard ratio (HR) was 16.0, with a 95% confidence interval (CI) ranging from 1.08 to 0.38. These data indicate that the use of both diazepam and anticoagulants can heighten the probability of experiencing psychological fragility. Additionally, a study conducted in Australia, referenced as [45], indicates that the probability of pre-frailty rises in correlation with the consumption of antagonistics and tranquilizers, especially diazepam. The study examined a group of males who live in the neighborhood and are at least 70 years old (with an average age of 76.9 ± 5.5 years). Over the course of two years, every small increase in the Pharmaceutical Stress Index was linked to a 1.73-fold increase in the chances of moving from a stable state to a pre-frail nation, with a 95% confidence interval (CI) spanning from 1.30 to 2.31. The Pharmaceutical Load Index quantifies the level of dependence on sedatives, specifically anticoagulants and sedatives. Increased exposure to these medications can heighten the probability of pre-frailty, potentially resulting in frailty.

These medications also elevate the likelihood of experiencing fractures and falling. A systematic review of twenty-five research papers examining fracture probability in older individuals revealed that diazepam usage was linked to a heightened risk of fractures, with an estimated risk of 1.26. Furthermore, [47] conducted an overview using information from elderly patients who had fallen and suffered injuries. They discovered that these people had a higher likelihood of using diazepam. The likelihood of these patients utilizing non-benzodiazepine sedatives was considerably greater (OR 1.24, 95% CI 1.05–1.48). Searching for research investigating the advantages of medication use for frailty was not feasible. However, a placebo-controlled study was conducted by [48] with a sample of 65 normal people aged \geq 60 years. The objective was to investigate the impact of MK-677, a gastric mimic that enhances the production of growth hormone. Treatment with MK-677 for one year resulted in a reduction may be efficacious for sarcopenia.

Reference	Advantages	Drawbacks
[30]	The prevalence of frailty included 8.2% among individuals diagnosed with sarcoma according to the EWGSOP definition, 15.7% among those diagnosed according to the FNIH definition, and 10.4% among those diagnosed according to the FNIH's established standards.	Sarcopenia demonstrates a moderate sensibility (10%) but an exceptionally high precision (>97%) for diagnosing frailty. Based on the research's results, sarcoma is not a reliable biomarker for frailty. However, a lack of dementia may be useful in excluding the presence of frailty.
[31]	The investigation also found that individuals had higher rates of sarcoma, whereas women had higher incidences of frailty. 42.1% of individuals diagnosed with sarcoma according to the European Working Group on Sarcopenia in Older People (EWGSOP) parameters were classified as weak according to the requirements set by the Cardiovascular Health Study (CHS); however, 25.0% were classified as weak depending on the Frailty Measure.	The prevalence of sarcoma as identified by the European Working Group on Sarcopenia in Adults (EWGSOP) was 36.4% among individuals who fulfilled the frailty requirements established by the Cardiovascular Health Study (CHS) and 20.0% among those who fulfilled the requirements of the Frailty Assessment.
[32]	Based on the CHS requirement, it was reported that 8.1% of people had sarcopenia, while 10.6% were identified as feeble.	Among the participants, 56.8% exhibited pre-frailty. 50.0% of the patients diagnosed with sarcopenia exhibited frailty, whereas 37.9% of individuals diagnosed with frailty were also found to have sarcopenia.
[33]	The researchers discovered that frailty had a substantial impact on the chances of dying, with a total odds proportion of 2.34 (95% CI 1.77–3.09) and an associated risk of 1.83 (95% CI 1.68–1.98).	Frailty is known to enhance the probability of developing Alzheimer. The analysis demonstrated a strong correlation between frailty and higher mortality rates at thirty days, ninety days, and a year after surgery, as well as with issues following surgery and longer hospitalizations.
[34]	The research encompassed individuals having heart, malignancy, overall, arterial, and broken hip procedures. The analysis demonstrated a strong correlation between frailty and higher mortality rates during a 30-day timeframe.	The analysis demonstrated a strong correlation between frailty and higher mortality rates at thirty days, ninety days, and one year. Additionally, frailty was found to be linked to difficulties with surgery and longer hospital stays.
[35]	The study included 1,754 older individuals living in the surrounding area who did not have diabetes of any kind at the beginning of the trial. The individuals were classified as fragile, pre- frail, or non-frail based on the CHS standards.	Pre-frailty was found to have a significant correlation with an increased likelihood of acquiring coronary artery disease. Additionally, frailty was found to have a separate relationship with the risk of

Table 1:	Compression	of related	work and t	he existing	work
I abic I.	Compression	of formed	work und t	ne existing	WOIN

		coronary artery disease.
[36]	A longitudinal study was conducted in France with individuals aged 70 years or older who lived in the neighborhood. The mean age of the participants was 83.0 ± 7.5 , and 59.4% of them were women. The investigation also included individuals ages around 50 and 75 years old, and the odds ratio (OR) for multiple medications was found to be 2.30 (95% confidence interval [CI] 1.60-3.31), while the OR for hyperpolypharmacy was 4.97 (95% CI 2.97– 8.32).	The use of multiple drugs (5–9) was found to be related to a 1.77 times higher chance of frailty, according to the CHS criterion. Additionally, the use of a large number of prescriptions (≥10 medicines) was discovered to be linked with a 4.47 times higher chance of frailty. Within a research investigation, a group of males who reside in the neighborhood and are at least seventy years old were examined.
[37]	During the observation period, individuals who were prescribed between four and six drugs had a higher probability of developing frailty compared to those who were prescribed 0 to 3 prescriptions. Moreover, this probability was even more for individuals using greater than seven medicines.	In an 8-year monitoring group analysis, comparable findings were observed, despite the comparatively youthful age of the group (using an average age of 60).
[38]	A group of 1705 men ages seventy years or older (with an average age of 76.9 + 5.5 years) who lived in the surrounding area were studied. Among them, 9.5% were classified as feeble.	These qualitative investigations offer proof that multiple medications are a contributing factor to frailty.
[39]	The optimal threshold to estimate frailty was determined to be 6, with an accuracy of 61.7%, precision of 52.4%, and an area over the curve of 0.58. Since both investigations utilized the CHS parameters to identify frailty.	Through the curve of receiver operating characteristics evaluation, it was determined that a threshold of 6.5 yielded the greatest predictive accuracy for frailty (with an accuracy of 47.5%, an accuracy of 87.5%, and a region underneath the curve of 0.70).
[40]	A group of 1705 men aged seventy years or over (with an average age of 76.9 + 5.5 years) who lived in the surrounding area were studied. Among them, 9.5% were classified as feeble.	The variation in the threshold for eligibility can be mostly attributed to variables in the cohort, such as variations in gender, age, and the distinction between one cohort being neighborhood residents and the other consisting of elderly outpatient care. Regardless, the research indicates that the threshold for the number of drugs lies between six and seven
[41]	Investigated the correlation between frailty, depressive disorders, and the utilization of antidepressants in a group of 27,652 women between the ages of 65 and 79 who did not exhibit frailty at the beginning of the study. During the course of three years of observation, around 15% of the subjects developed frailty.	The odds ratio (OR) for frailty among antidepressant consumers who were melancholy was 3.63 (95% confidence interval (CI) 2.37–5.55), while the OR for antidepressant consumers who did not suffer from depression was 1.73 (95% CI 1.41– 2.12).
[42]	The subsequent research primarily investigated the impacts of drug utilization on elderly individuals who are in good health.	between higher continuous usage and an elevated likelihood of acquiring Alzheimer (with the greatest continuous usage having a hazard ratio of 1.54).
[43]	The study examined a group of males who live in the neighborhood and are at least seventy years old (with an average age of 76.9 ± 5.5 years).	each incremental rise in the Drug Load Measure was linked to a 1.73-fold rise in the odds ratio (OR) of migrating from a stable condition to a pre-frail nation, with a CI (confidence interval) of 95% ranging from 1.30 to 2.31.
[44]	Treatment of MK-677 at 12 months resulted in a reduction in belly fat and a slight rise in mass	Searching for research investigating the advantages of medication use for frailty

3. The Implementation Model of Frailty CDSS

As illustrated in Figure 1, the recommendations and requirements can be divided into three groups. The first prerequisite relates to the clinical recommendations about the relevant CDSS information and material. The use of an active and passive alert mechanism, as well as the integration of the Hospital Information System and CDSS (HIS), are all part of the second set of performance standards. The final set of performance standards concerned the caliber of the recommendations that the CDSS produced.

To integrate with HIS and support medical evidence, the clinical standards and laws of the hospital must be transformed into electronic formats. The clinical protocols, standards, and guidelines are typically general and not customized to patients, which makes this a highly challenging situation. The hospital should appoint professionals to create trustworthy clinical rules in order to solve this difficulty.

The key factors that reduce or weaken the utility of such a system are largely the confusing information content, the minimal alert specificity, the system's high sensitivity, and its generic nature. Therefore, the contents should be evaluated while computerizing the clinical rules/guidelines in order to ensure the validity of alerts and messages and the accuracy of alerts [49].



Figure 1: Circumstances for CDSS Achievement

CDSS is based on clinical expertise that is subject to ongoing change. Therefore, in order to sustain the usefulness of CDSS, a framework for updating clinical knowledge and reviewing it connected to rules and recommendations needs to be established [49].

4. Frailty Assessment

Frailty evaluation offers a theoretical framework that primary care doctors can use to create a thorough strategy for evaluating and treating elderly patients with complicated multimorbidities in a straightforward and organized manner. The global lack of pertinent data and evidence on the health of the elderly, which impedes the creation and assessment of appropriate policies and programs for them, supports the necessity of employing frailty measurement techniques [50].

Frailty assessment has a variety of suggested models and concepts that can be used in different contexts (Table 2). According to frailty assessments, older people are more likely to experience negative health outcomes, such as mortality, impairment, decreasing mobility, falls, hospitalization, and death. The phenotypic definition of frailty and the accumulation of deficits definition of frailty are the most reliable and extensively used approaches to quantify frailty. The understanding of aging and the frailty mechanism is a key distinction between these two frailty conceptualizations [51].

		on of the enagnosis and symptoms of manty [51]
No	Diagnosis	Symptoms
1	Unintentional Weight loss	If you lost over 5% of your body weight unintentionally in the past year or have a BMI under 18.5 kg/m2, you meet the requirements for weight loss. Equipment includes a stadiometer and a scale for body weight.
2	Exhaustion	Felt unusually weak or exhausted all the time or most of the time, or reported having a level of energy below three.
		Meets criteria for slow walking speed over 4 meters if: Men
3	Slowness	≤ 0.65 m/s for height $\leq 1/3$ cm (68 inches) ≤ 0.76 m/s for height > 173 cm (68 inches) Women
5	510 111055	Height 159cm (63 inches): 0.65 m/s; height >159cm: 0.76 m/s (63 inches) Equipment: a stopwatch and a 4-meter course.
		The participant tries to walk twice the length of a 4-meter track. use the mean of two experiments.
4	Low Activity	Men: <128 kcal of weekly physical activity-based energy expenditure (6 items) Women: <90 kcal of weekly physical activity based energy expenditure (6
5	Weakness	items)
5	Weakiness	Meets cinena for grip strength weakness it. Men 20 kg for PMI 24 1 26 kg for PMI 26 1 28 kg for PMI 20 kg
		Women should weigh no more than 17 kg for BMIs of 23 to 26 and no more than 17.3 kg for BMIs of 26 to 29.
		Hand dynamometer (Jamar) as equipment Using the dominant hand, the participant tries to squeeze the dynamometer three times in all.
		Use maximal score with dominant hand
6	Weight loss	Regardless of intent to lose weight, lost over 5% of body weight in the last two to three years.
7	Poor endurance	Equipment includes a stadiometer and a scale for body weight.
	/ exhaustion	Rand-36 Vitality Scale score of 55 out of 100. Evaluate how often and how long you walk and engage in light, moderate, and vigorous exercises. In order to determine who meets the criteria for this component, the kcal of weekly energy expenditure was computed (metabolic equivalent task hours score = kcal/wk x kg).
8	Physical activity	If the answer to the question in the last two years, did you lose five pounds or more without intending to at any point? was Yes, you have lost over 5% of your body weight
9	Unintentional	Equipment includes a stadiometer and a scale for body weight.
	weight loss	Gait Speed Test: A person tries to walk a 4-meter course at their normal pace, as if they were going to the shop while strolling down the street.
10	Usual Gait Speed	The chair stand test involves five unsuccessful attempts to get out of a chair without using one's arms.
11		
	Repeated Chair Stands	A person tries to stand side-by-side with their feet touching for 10 seconds. How often did you feel fatigued over the previous four weeks? 1 denotes always, 2 denotes most of the time, 3 denotes occasionally, 4 denotes occasionally, and 5 denotes power. Answers of 1 or 2 receive a 1 while
12		all other responses receive a 0.
	Standing Balance	Resistance: By yourself and not using aids, do you have any difficulty walking up 10 steps without resting? 1 = Yes, 0 = No
13		,

Table 2: The classification of the diagnosis and symptoms of frailty [51]

	Fatigue	Do you have any trouble walking several hundred yards by yourself and without any aids? 1 = Yeah, $0 = $ No.
14	Resistance	Illnesses: Participants are asked, has a doctor ever tell you that you had [illness]? for 11 different illnesses. 1 = Yeah, 0 = No.
15	Ambulation	Weight loss: How much do you weigh without shoes and with your clothes on? [Actual weight] How much did you weigh in (MO, YR) one year ago, both in your clothes and without shoes? (Weight from a year ago)
16	Illnesses Loss of weight	The formula for calculating percentage weight change is [[weight 1 year ago - current weight]/weight 1 year ago]]. * 100. Percent change greater than 5 (indicating a 5% weight decrease) is scored as 1, and less than 5 is scored as 0.

4.1. Frailty Diagnosis

The diagnosis of frailty can be done in two ways. The first is the phenotypic model, which uses the CHS's constituent parts to gauge frailty. The frailty index is presented by the second model, the accumulated deficit model. [52].

Unintentional weight loss, self-reported tiredness, weakness (low grip strength), inadequate physical exercise, and sluggish walking speed are indicators of age-related physical decline [53]. According to this model, having one or two of the aforementioned criteria indicates pre-frail status, having three or more elements denotes frailty status, and having no factors at all suggests robust status. According to this model, defining physical frailty follows a common methodology. A review by [54] revealed that there were no established standards for evaluating each component. It also mentioned the existence of countless additional criteria that have the same phenotype [54].

The percentage of accumulated deficits in the elements favoring health and independence is described by the frailty index, as shown in [55]. On the grounds that such accumulated deficits reflect frailty level and reflect characteristics at the level of the whole organism rather than any given functional deficiency, they proposed that the Frailty Index be constructed using more than 30 variables (related to symptoms, signs, activities of daily living, disease, cognitive impairment, etc.). Category, ordinal, and interval variables can be coded with 0 denoting no deficit and 1 denoting a complete deficiency, according to [56].

In addition to the ones mentioned above, there are a number of thorough geriatric evaluations, the Edmonton Frail Scale being one of the more well-known (Table 2) [51].

4.2. Frailty and specific diseases

Frailty has been linked to orthostatic hypotension and orthostatic intolerance, both of which increase the risk of falling. [57] evaluated the association between orthostatic hypotension, orthostatic intolerance, and frailty using data from 5692 participants in the Irish Longitudinal Study on Aging who were over 50 years old (TILDA). According to the Cardiovascular Health Study (CHS) criteria, 4.3% of these people were classified as frail, 6.1% as having orthostatic hypotension, 6.7% as having orthostatic intolerance, and 34.5% as being pre-frail. Orthostatic hypotension and orthostatic intolerance were more common in people who were weak (8.9% and 14.3%, respectively) than in participants who were strong (5.0% and 5.7%).

The HYVET study—Hypertension in the Very Elderly Trial—is the trial in question. According to HYVET, a diuretic can reduce the risk of stroke, cardiovascular events, all-cause mortality, and cardiovascular mortality in people with hypertension who are under the age of 80. In HYVET, 2,656 people who were classified as fragile at baseline underwent a subanalysis by [43]. According to their findings, there is no proof that frailty alters the effectiveness of antihypertensive therapy in reducing stroke and cardiovascular events.

The Systolic Blood Pressure Intervention Trial is the second trial (SPRINT). SPRINT comprises people under the age of 50 who have at least one heart disease risk factor (however, individuals with diabetes were excluded). It has been demonstrated that intensive treatment (treating to a systolic blood pressure target of 120 mmHg) is more beneficial for lowering the risk of cardiovascular events, cardiovascular mortality, and all-cause mortality [58] than standard treatment (a target of 140 mmHg).

Results from the CHS, as well as other prospective cohort studies and cross-sectional investigations, have shown a connection between diabetes and frailty. A prospective cohort study conducted in Spain looked at non-institutionalized people over the age of 60. Participants with diabetes were more likely to become feeble during an average 3.5-year follow-up (OR 2.18; 70) [59].

A cross-sectional examination of 121 COPD patients who visited a COPD clinic in a Thai university hospital was conducted in [60]. They classified 7% of the COPD patients as fragile using the FRAIL scale, and they discovered that weariness was the most prevalent FRAIL scale component among the frail patients.

Although several studies have looked at the connection between frailty and chronic kidney disease (CKD), this clinical query concentrates on the association with non-dialysis CKD. A systematic analysis of cohort studies and observational studies that looked at how frailty affects CKD outcomes was done by [61]. Increased frailty or decreased physical function were linked to CKD (OR 1.30–3.12).

Numerous studies on dialysis patients point to a link between frailty and a reduction in ADLs. [48] looked at a sample of dialysis patients, 14.0% of whom met the CHS definition of frailty. There is a need for interventions to increase physical activity since patients with concomitant frailty were more likely (OR 11.35) than non-frail patients to need assistance with daily activities [62].

4.3. The Proposed Model Components of Frailty DSS

CDSSs have a highly diverse range of designs. The fundamental rules of architecture and design have also undergone significant modification during the past ten years. Clinical efficiency, utility, error prevention, likelihood of acceptability in the clinical setting, flexibility of architectures, cost-effectiveness, and additional attributes of CDSSs are connected to or directly affected by a number of CDSS characteristics, as shown in figure 2. Thus, it is crucial to describe CDSSs in a way that allows for the best understanding of their diversity. Knowing categorization presents a potent collection of fundamental facts that are helpful to CDSS designers and assessors when combined with an understanding of the general clinical decision-making processes mentioned above [63].

Figure 2 shows the following specifications: They consist of (1) the basis, which consists of the data available, the algorithm used to model the decision (which is non-knowledge-based), and the rules that are programmed into the system (which are knowledge-based). (2) Inference engine: This component applies programmed or artificial intelligence (AI)-determined rules and data structures to the clinical data of the patient to produce an output or action, which is then presented to the end user (in this case, a physician) through a communication mechanism.



Figure 2: Key interactions in knowledge-based and non-knowledge-based CDSS

4.4. Data Preprocessing

The data must be preprocessed before being used to create a model. The variables that a model can use from raw data are defined by preprocessing processes. Health care providers' specialized knowledge is crucial during the preprocessing stages to extract useful data's attributes and value. For instance, illness activity variables must be created because clinical care does not always follow study protocols and supporting surveys. Additionally, because composite endpoints are less helpful for CDS than specific endpoints that call for particular actions, health care experts may advise data scientists to steer clear of them. Additionally, selecting the proper time periods for the process of removing attributes from information, such as variations in changes over time in laboratory results, calls for expert expertise. Missing values and outliers can have significance that only a health care practitioner can recognize, even if doing so generally improves algorithm accuracy. The same is true of outliers.

4.5. Proposed Algorithm

After choosing the right data for the CDS system, the next step is to build a model (which employs an algorithm to characterize the relationship between components and outcomes in the data) using a predetermined computational method to derive from the data. Depending on how difficult the modeling assignment is, a phase of model training and a phase of model validation are frequently included in the model development process. In the training phase, a model is developed that best fits the data (makes the best predictions based on the training data), and in the validation phase, tests are done to determine the model's accuracy. The clinical research question determines what makes a successful prediction (identify all positive diagnoses). In the validation stage, it is customary to test the model using a fresh dataset. This could be a portion of the overall dataset that has never been seen before or a brand-new dataset.

The indicators rely on the assumptions of accurate positives (TP), false negatives (FN), real negatives (TN), and fake positives (FP). True positives represent the effectively estimated positive samples; false negatives demonstrate the effectively predicted favorable outcomes that have been erroneously determined to be adverse; true negatives demonstrate the properly

predicted negative samples; and false positives demonstrate the erroneously classified negative samples as positive by the method of estimation. The formulas for the different metrics used in this study are outlined in Table 2.

The relationships with death were stable throughout the tests conducted on changing structures, which aligns with previous experience using these replication strategies. Put simply, FI does not have to encompass a uniform inventory of elements across different investigations. The inadequate accumulation method for frailty possesses a notable combination of strength and convenience. Using standard methods and procedures, along with a sufficient number of flaws in different systems, makes it possible to find functional impairment (FI) in any dataset or clinical setting. In the setting of clinical studies, a frailty index (FI) can be established retroactively using pre-existing data. This approach offers several advantages: A) it lets researchers figure out how common frailty is among people in a current clinical study, either after the fact or in the future; B) it makes things easier for respondents by getting rid of the need to gather extra information about frailty; and C) it gets rid of the need for clinician evaluation when putting people into frailty groups [64].

4.6. Evaluation Metrics

The following measures were used to rate the supervised models' prediction abilities: Here, the terms true positive, true negative, false positive, and false negative rates, respectively, are abbreviated as TP, TN, FP, and FN [65].

_ True Positive Rate	=	$TPR = \frac{TP}{TP+FN}$
_ False Positive Rate	=	$FPR = \frac{TP}{FP+TN}$

Accuracy: For classification models, accuracy is a crucial measure. The test dataset in this study is balanced, so it will provide a decent indication of how well the model predicts outcomes.

	TP+TN
Accuracy =	TP+TN+FP+FN
F1 Score: F1	score is the harmonic mean of precision and recall. 2xPrecisionxRecall
F1score = where	Precision+Recall
	TP
Precision = And	TP+FP
	TP
Recall =	TP+FN

5. Result and Analysis

Various discrete approaches for evaluating frailty in research on patients have been proposed in the past few years. Frailty characteristics, evaluation tools that depend on interpretation, like the Medical Frailty Measure, and the FI based on a set of impairments are all common examples. A predetermined set of multiple criteria that evaluates the presence or absence of a variety of indicators, such as unintentional weight loss, expressed weariness, sluggish walking speed, weak grasp ability, and low levels of exercise, determines the frailty signature. Based upon these replies, a person is categorized into one of three frailty classifications: frail, prefrail, or non-frail. The Medical Frailty Measure utilizes a comprehensive evaluation of frailty, employing an emotional evaluation to assign individuals to one of nine groups ranging from excellent physical condition to extremely frail or fatally sick. Both of these methods necessitate the initial implementation of targeted data collection in an experimental medical environment, which could not be carried out in the case of past reviews or could not be perceived as achievable in the case of proactive data gathering.

In this case, we have employed the accumulation of deficiencies technique, which has many benefits in experimental situations. This technique has been extensively tested and applied to numerous worldwide demographic and healthcare databases. It encompasses a diverse array of healthcare disorders, including complications and impairments in physical and cognitive abilities. The main advantage of this approach is that it does not categorize frailty into a few separate states; rather, it gives a continuous pattern of frailty. This allows for a more precise analysis of the relationships between frailty, aging, other traits, and results. The deficiencyaccumulating FI technique is naturally flexible because it lets you use current data as long as a lot of deficiencies have been gathered from different systems. This is especially important for clinical studies. Prior research has shown that a Frailty Index (FI) can be created by utilizing information from preexisting demographic and medical data bases, namely data that would typically be gathered during regular health evaluations of elderly individuals. Functional images (FIs) were additionally produced and utilized in certain research studies focused on heart disease and persistent illnesses. We have expanded this process to create and verify a Frailty Index (FI) via data that is easily accessible from an individual's medical records, typically collected during an examination or the beginning of a vaccine study. These studies are distinct from beneficial studies as they primarily aim to prevent diseases in a group of individuals who usually don't have any specific medical conditions. Therefore, the frailty index (FI) method of quantifying frailty is highly feasible to incorporate into research studies without adding extra load on participants and operations.

We incorporated a total of 16 factors into our financial institution (FI). Typically, as the number of factors in a forecasting interval (FI) increases, the accuracy of the predictions also increases. The widely acknowledged lowest amount of deficiencies is around 30, while consistency and reliable forecasting of events are often optimal with 40 or more deficiencies. The FI technique enables the combining of a substantial amount of information by incorporating numerous health deficiencies, thus lowering complexity. An often-asked issue pertains to the absence of weighting in the ranking. There are several factors contributing to this phenomenon. Eliminating the use of weights improves the simplicity of calculations and allows for greater applicability across different datasets. Numerous confirmations conducted in various scenarios and databases have consistently shown that the use of weighing is unnecessary. This can also be comprehended by considering the inclusion of numerous deficiencies across different systems, which enables self-weighting (for example, a severe medical condition tends to be linked with useful and symptomatic consequences, thus resulting in more deficiencies, whereas a less severe health scenario would not). It is important to mention that since this FI (Frailty Index) was developed from a trial on a vaccination, we skipped over particular hazards for herpes or ancestral products, as those are often not considered in FI according to established standards. The primary objective of a frailty index (FI) used in vaccine trials is to establish a comprehensive indicator of frailty. rather than an individualized evaluation of vulnerability to a particular disease.

The qualities of the FI exhibit consistency with the features of the FI that have been extensively duplicated and maintained throughout datasets. These involve gamma shipping, a tendency for the range to become more asymmetrical as age increases, and fragility limits of roughly 0.8.35. According to previous research on gender disparities, the level of frailty was shown to be greater in women compared to men. Survival analysis revealed that the probability of mortality was greater for feeble males in comparison to fragile females. This finding aligns with previous research indicating that although males tend to have fewer deficiencies compared to women, the impact of deficits accumulating on mortality is higher for men. Mortality was significantly predicted by being female, having younger ages, and having less FI. Frailty was a strong predictor of survival regardless of age (p < 0.001),

indicating a heightened susceptibility to negative health effects for people that is not influenced by their actual age.

The categorization models were created using six distinct algorithms: ID3, C4.5, Logistic Regression (LR), Random Forests (RF), CART, and Decision Trees. After stratified six-fold cross-validation, each method was initially validated using samples from all aspects of frailty diagnosis.

Figure 3 displays the accuracy of the unintentional weight loss feature. Our goal is to select the model that is most accurate and capable of telling the two classes apart. The Random Forests (RF) model was found to be the best one since it outperformed the competition in terms of accuracy (96.88%).



Figure 3: Accuracy rate for unintentional weight loss

Figure 4 demonstrates the F1 score of the unintentional weight loss features utilizing the six different techniques. The model was found to be the best one since it outperformed the competition in terms of F1 score (0.978).



Figure 4: F1 score for unintentional weight loss

Figure 5 shows the accuracy of the slowness feature. Our goal is to select the model that is most accurate and capable of telling the two classes apart. The Random Forests (RF) model was found to be the best one since it outperformed the competition in terms of accuracy (98.47%).



Figure 5: Accuracy rate for slowness

Figure 6 shows the F1 score of slowness features employing the six techniques. Our goal is to select the model that is most accurate and capable of telling the two classes apart. The model was found to be the best one since it outperformed the competition in terms of F1 score (0.984).



Figure 6: F1 score for slowness

Figure 7 shows the accuracy of the poor endurance/exhaustion feature. Our goal is to select the model that is most accurate and capable of telling the two classes apart. The Random Forests (RF) model was found to be the best one because it outperformed the others in terms of accuracy (97.48%).



Figure 7: Accuracy rate for poor endurance/exhaustion

Figure 8 shows the F1 score for poor endurance/exhaustion features employing the six techniques. Our goal is to select the model that is most accurate and capable of telling the two classes apart. The model was found to be the best one because it outperformed the others in terms of F1 score (0.938).



Figure 8: F1 score for poor endurance/exhaustion

Figure 9 shows the accuracy of the Repeated Chair Stands feature. In order to effectively discriminate between the two groups, we want to select the most accurate model possible. It was found that the Random Forests (RF) model is the best one because it outperformed the others in terms of accuracy (94.26%).



Figure 9: Accuracy rate for repeated chair stands

Figure 10 shows the F1 Score of Repeated Chair Stands features employing the six strategies. In order to effectively discriminate between the two groups, we want to select the most accurate model possible. It was found that the model is the best one because it outperformed the others in terms of F1 score (0.952).



Figure 10: F1 score for repeated chair stands

Figure 11 shows the accuracy of the age feature. The best model that is capable of clearly differentiating between the two classes is what we are trying to find. Random Forests (RF), which outperformed the competition in terms of accuracy, was found to be the best model (93.12%).



Figure 11: Accuracy for age

Figure 12 shows the F1 Score of Age features, making use of the six techniques. The best model that is capable of clearly differentiating between the two classes is what we are trying to find. The competition in terms of F1 was found to be the best model of F1 score (0.972).



Figure 12: The F1 score for age

Table 3: Compression of Survival	Analyses by	Machine	Learning	Techniques'	Modeling
Difficulty					

Algorithm	Training time (sec)	Throughput (samples per sec)
ID3	0.13413	1955632
LR	33.122	5269332
RF	67.321	94131
DT	2.5123	6508671
C4.5	0.547	48897
CART	0.623	58798

There are no restrictions on our investigation. Since frailty wasn't originally defined as a particular metric in the early investigations, the Frailty Index (FI) was created using the data items that were accessible. However, it is important to note that the current exercise focuses on the retrospective evaluation of frailty. While it was shown before that the trials included patients with varying levels of frailty, it should be noted that the frailest patients wouldn't have been eligible to participate, as is typically the case in clinical studies. The strongest points of this study are its extensive study population, consisting of over 20,000 individuals from various age groups and multiple foreign locations. Additionally, the data collection for medical histories and outcomes is rigorous, particularly within the framework of a vaccine clinical experiment.

Conclusions

As far as we comprehend, it's the first occasion that the FI has been used retrospectively in a large vaccination investigation. The possible broad relevance of this method is especially pertinent due to the growing healthcare impact and significance of vaccinations for elderly people. This is because frailty, which is increasingly acknowledged by consumers, doctors, those making decisions, and authorities, has significant effects on the effectiveness and safety of actions like vaccinations and medication. Hence, it is crucial to possess the ability to categorize frailty within the sample population, either by diagnostic means or to facilitate the selective enrollment of researchers based on varying degrees of frailty. Clinical trials frequently lack sufficient representation of frail people, so even if they participate, their level of frailty stays undisclosed. The use of frailty indicators in clinical studies is a significant advancement in comprehending the effectiveness of therapies on frail older persons.

Once health-care providers are persuaded of the additional advantages of CDSS for their patients, they may recognize the value and necessity of embracing the rising role that data collection, interpretation, and curation play and move beyond the idea that doctors know best to the idea that doctors do best. CDSS plays a big part in patient safety and assists doctors in making decisions. Additionally, it raises the standard of medical care. In our study, we demonstrate the significant influence of CDSS on healthcare as well as the major difficulties in implementing CDSS, such as financial, moral, practical, and social issues. The conditions for effective CDSS installation have also been covered. According to this study, a potent combination of five characteristics—unintentional weight loss, slowness, weak endurance or exhaustion, frequent chair stands, and age-helps to effectively estimate the mortality rates of individuals who are impacted by frailty. The most accurate mortality predictions have been made using a variety of machine learning methods. The model's interpretability, which may be important in the therapeutic situation, is provided by the Random Forests (RF) algorithm's feature significance. Five different situations were used to extensively verify the proposed model's robustness. Despite its flaws, CDSS has developed into a potent instrument for raising the standard of care in the healthcare industry. In order to solve the issues raised here and in earlier studies, we anticipate that future generations of CDSS will be more capable and usable. Frailty DSS will serve as the central element of a web-based forecasting framework for the future. This platform will possess the capability to forecast the detection of and administer therapy for multiple diseases. Additionally, it will have the ability to incorporate a forecasting mechanism (PM) and an education module (LM) into the FrailtyDSS framework.

The objective of the LM is to acquire knowledge from previously recorded historical information. Additionally, it is important to investigate the potential combinations among the individual's different medications to enhance assistance with decision-making.

Acknowledgements

Authors would like to thank the University of Baghdad, College of Nursing, Department of Basic Sciences, Middle Technical University, Technical Institute-Suwaira, Department of Computer Systems and LR-OASIS, National Engineering School of Tunis, University of Tunis El Manar for the support given during this work.

References

- [1] B. A. Alqahtani and T. A. Nasser, "Assessment of frailty in Saudi community-dwelling older adults: validation of measurements," *Annals of Saudi medicine*, vol. 39, no. 3, pp. 197-204, May.2019. Doi: 10.5144/0256-4947.2019.197.
- [2] R. J. Gobbens and I. Uchmanowicz, "Assessing frailty with the Tilburg Frailty Indicator (TFI): A review of reliability and validity," *Clinical Interventions in Aging*, pp. 863-875, May.2021. Doi: 10.2147/CIA.S298191.
- [3] B. A. Alqahtani *et al.*, "Prevalence of frailty in the middle east: systematic review and metaanalysis," in *Healthcare*, MDPI, vol. 10, no. 1, p. 108, Jan.2022. Doi: 10.3390/healthcare10010108.
- [4] F. Mehrabi and F. Béland, "Frailty as a moderator of the relationship between social isolation and health outcomes in community-dwelling older adults," *International Journal of Environmental Research and Public Health*, vol. 18, no. 4, p. 1675, Feb. 2021. Doi: 10.3390/ijerph18041675.
- [5] M. Kim and C. W. Won, "Cut points of chair stand test for poor physical function and its association with adverse health outcomes in community-dwelling older adults: A cross-sectional and longitudinal study," *Journal of the American Medical Directors Association*, vol. 23, no. 8, pp. 1375-1382. e3, Aug.2022. Doi: 10.1016/j.jamda.2021.11.007.
- [6] T.-L. To, T.-N. Doan, W.-C. Ho, and W.-C. Liao, "Prevalence of frailty among communitydwelling older adults in Asian countries: a systematic review and meta-analysis," in *Healthcare*, MDPI, vol. 10, no. 5, p. 895, May. 2022.doi: 10.3390/healthcare10050895.
- [7] N. Sukkriang and K. Somrak, "Correlation between mini nutritional assessment and anthropometric measurements among community-dwelling elderly individuals in rural Southern Thailand," *Journal of Multidisciplinary Healthcare*, pp. 1509-1520, Jun.2021. Doi: 10.2147/JMDH.S315652.
- [8] Y. Yuan *et al.*, "The identification and prediction of frailty based on Bayesian network analysis in a community-dwelling older population," *BMC geriatrics*, vol. 22, no. 1, p. 847, Nov.2022. Doi: 10.1186/s12877-022-03520-7.
- [9] N. Almohaisen *et al.*, "Prevalence of undernutrition, frailty and sarcopenia in community-dwelling people aged 50 years and above: Systematic review and meta-analysis," *Nutrients*, vol. 14, no. 8, p. 1537, Apr.2022. Doi: 10.3390/nu14081537.
- [10] T. Van Der Ploeg, R. J. Gobbens, and B. E. Salem, "Bayesian techniques in predicting frailty among community-dwelling older adults in the Netherlands," *Archives of gerontology and geriatrics*, vol. 105, p. 104836, Feb. 2023. Doi: 10.1016/j.archger.2022.104836.
- [11] T. Goto, C. A. Camargo, M. K. Faridi, R. J. Freishtat, and K. Hasegawa, "Machine learning– based prediction of clinical outcomes for children during emergency department triage," *JAMA network open*, vol. 2, no. 1, pp. e186937-e186937, Jan.2019. Doi: 10.1001/jamanetworkopen.2018.6937.
- [12] Y. Raita, T. Goto, M. K. Faridi, D. F. Brown, C. A. Camargo, and K. Hasegawa, "Emergency department triage prediction of clinical outcomes using machine learning models," *Critical care*, vol. 23, no. 1, pp. 1-13, Feb.2019. Doi: 10.1186/s13054-019-2351-7.
- [13] P. Wolff, S. A. Ríos, and M. Graña, "Setting up standards: A methodological proposal for pediatric Triage machine learning model construction based on clinical outcomes," *Expert Systems with Applications*, vol. 138, p. 112788, Jul.2019. Doi: 10.1016/j.eswa.2019.07.005.
- [14] S. Hwang and B. Lee, "Machine learning-based prediction of critical illness in children visiting the emergency department," *PLoS One*, vol. 17, no. 2, p. e0264184, Feb.2022. Doi: 10.1371/journal.pone.0264184.
- [15] R. Sánchez-Salmerón *et al.*, "Machine learning methods applied to triage in emergency services: A systematic review," *International Emergency Nursing*, vol. 60, p. 101109, Jan.2022. Doi:

10.1016/j.ienj.2021.101109.

- [16] T. Hatachi *et al.*, "Machine Learning–Based Prediction of Hospital Admission Among Children in an Emergency Care Center," *Pediatric Emergency Care*, Feb .2022. Doi: 10.1097/PEC.00000000002648.
- [17] M. R. Sills, M. Ozkaynak, and H. Jang, "Predicting hospitalization of pediatric asthma patients in emergency departments using machine learning," *International Journal of Medical Informatics*, vol. 151, p. 104468, July. 2021. Doi: 10.1016/j.ijmedinf.2021.104468.
- [18] R. Gutiérrez-Zúñiga *et al.*, "Structural brain signatures of frailty, defined as accumulation of self-reported health deficits in older adults," *Frontiers in Aging Neuroscience*, vol. 15, Jan. 2023, Doi: 10.3389/fnagi.2023.1065191.
- [19] M. K. Andrew, S. Matthews, J. H. Kim, M. E. Riley, and D. Curran, "An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials," *Clinical Interventions in Aging*, vol. 17, pp. 1261–1274, Aug. 2022, Doi: 10.2147/cia.s364997.
- [20] D. A. Anggoro and S. Hajiati, "Comparison of Performance Metrics Level of Restricted Boltzmann Machine and Backpropagation Algorithms in Detecting Diabetes Mellitus Disease," *Iraqi Journal of Science*, vol. 64, no. 2, pp. 907–921, Feb. 2023. Doi: 10.24996/ijs.2023.64.2.35.
- [21] N. J. Habeeb, "Medical Image Denoising with Wiener Filter and High Boost Filtering," *Iraqi Journal of Science*, vol. 64, no. 6, pp. 3123–3135, Jun. 2023. Doi: 10.24996/ijs.2023.64.6.40
- [22] K. J. W. Tang, C. K. E. Ang, T. Constantinides, V. Rajinikanth, U. R. Acharya, and K. H. Cheong, "Artificial intelligence and machine learning in emergency medicine," *Biocybernetics and Biomedical Engineering*, vol. 41, no. 1, pp. 156-172, Jan.2021. Doi: 10.1016/j.bbe.2020.12.002.
- [23] M. Fernandes, S. M. Vieira, F. Leite, C. Palos, S. Finkelstein, and J. M. Sousa, "Clinical decision support systems for triage in the emergency department using intelligent systems: a review," *Artificial Intelligence in Medicine*, vol. 102, p. 101762, Jan. 2020. Doi: 10.1016/j.artmed.2019.101762.
- [24] H. Kurosawa *et al.*, "The association between prehospital vital signs of children and their critical clinical outcomes at hospitals," *Scientific Reports*, vol. 12, no. 1, p. 5199, Mar.2022, Doi: 10.1038/s41598-022-09271-0.
- [25] H. L. Ekstrom *et al.*, "Development of a clinical decision support system for pediatric abdominal pain in emergency department settings across two health systems within the HCSRN," *eGEMs: The Journal of Electronic Health Data and Methods*, vol. 7, no. 1, pp. 1-9, Apr.2019. Doi: 10.5334/egems.282.
- [26] H. S. Hameed, J. H. Yenzeel, and M. A. Sabbah, "Evaluation of the level of some Interleukins in serum of Iraqi patients with Endometrial Carcinoma," *Iraqi Journal of Science*, vol. 64, no. 9, pp. 4366–4374, Sep. 2023. Doi: 10.24996/ijs.2023.64.9.6.
- [27] M. H. Alwan and S. Z. Hussein, "Evaluation of Oxidative Stress in Iraqi Male Patients with Myocardial Infarction and Type 2 Diabetes Mellitus," *Iraqi J Sci*, vol. 64, no. 10, pp. 4918–4929, Oct. 2023. Doi: 10.24996/ijs.2023.64.10.3.
- [28] N. Peiffer-Smadja *et al.*, "Machine learning for clinical decision support in infectious diseases: a narrative review of current applications," *Clinical Microbiology and Infection*, vol. 26, no. 5, pp. 584-595, May.2020. Doi: 10.1016/j.cmi.2019.09.009.
- [29] Y. A. Fakri and S. A.-K. Al-Jowari, "Antithyroid Peroxidase and Thyroid Hormones in a Sample of Iraqi Patients with Type 2 Diabetic Mellitus," *Iraqi J Sci*, vol. 64, no. 4, pp. 1618–1624, Apr. 2023. Doi: 10.24996/ijs.2023.64.4.5.
- [30] N. Mielke, A. Schneider, D. Huscher, N. Ebert, and E. Schaeffner, "Gender differences in frailty transition and its prediction in community-dwelling old adults," *Scientific reports*, vol. 12, no. 1, p. 7341, May.2022. Doi: 10.1038/s41598-022-11358-7.
- [31] J. Alcazar *et al.*, "Relation between leg extension power and 30-s sit-to-stand muscle power in older adults: validation and translation to functional performance," *Scientific reports*, vol. 10, no. 1, p. 16337, Oct.2020. Doi: 10.1038/s41598-020-73395-4.
- [32] Y. Taniguchi *et al.*, "Association of dog and cat ownership with incident frailty among community-dwelling elderly Japanese," *Scientific reports*, vol. 9, no. 1, p. 18604, Dec.2019. Doi: 10.1038/s41598-019-54955-9.

- [33] C. Mazo, C. Kearns, C. Mooney, and W. M. Gallagher, "Clinical decision support systems in breast cancer: a systematic review," *Cancers*, vol. 12, no. 2, p. 369, Feb.2020. Doi: 10.3390/cancers12020369.
- [34] K. Miller *et al.*, "Interface, information, interaction: a narrative review of design and functional requirements for clinical decision support," *Journal of the American Medical Informatics Association*, vol. 25, no. 5, pp. 585-592, Nov.2018. Doi: 10.1093/jamia/ocx118.
- [35] P. A. Pawloski, G. A. Brooks, M. E. Nielsen, and B. A. Olson-Bullis, "A systematic review of clinical decision support systems for clinical oncology practice," *Journal of the National Comprehensive Cancer Network*, vol. 17, no. 4, pp. 331-338, Jun.2019. Doi: 10.6004/jnccn.2018.7104.
- [36] S. M. Araujo, P. Sousa, and I. Dutra, "Clinical decision support systems for pressure ulcer management: systematic review," *JMIR medical informatics*, vol. 8, no. 10, p. e21621, Oct.2020. Doi: 10.2196/21621.
- [37] M. Beauchemin, M. T. Murray, L. Sung, D. L. Hershman, C. Weng, and R. Schnall, "Clinical decision support for therapeutic decision-making in cancer: A systematic review," *International journal of medical informatics*, vol. 130, p. 103940, Oct.2019. Doi: 10.1016/j.ijmedinf.2019.07.019.
- [38] J. L. Kwan *et al.*, "Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials," *BMJ*, vol. 370, Sep.2020. Doi: 10.1136/bmj.m3216.
- [39] K. Miller *et al.*, "The design of decisions: Matching clinical decision support recommendations to Nielsen's design heuristics," *International journal of medical informatics*, vol. 117, pp. 19-25, Sep. 2018. Doi: 10.1016/j.ijmedinf.2018.05.008.
- [40] B. C. Stagg *et al.*, "Special commentary: using clinical decision support systems to bring predictive models to the glaucoma clinic," *Ophthalmology Glaucoma*, vol. 4, no. 1, pp. 5-9, Jan. 2021. Doi: 10.1016/j.ogla.Feb.2021.08.006.
- [41] S. Chima, J. C. Reece, K. Milley, S. Milton, J. G. McIntosh, and J. D. Emery, "Decision support tools to improve cancer diagnostic decision making in primary care: a systematic review," *British Journal of General Practice*, vol. 69, no. 689, pp. e809-e818, Dec.2019. Doi: 10.3390/antibiotics12010136.
- [42] S. Van de Velde *et al.*, "The GUIDES checklist: development of a tool to improve the successful use of guideline-based computerised clinical decision support," *Implementation Science*, vol. 13, pp. 1-12, Jun.2018. Doi: 10.1186/s13012-018-0772-3.
- [43] E. L. Stone, "Clinical decision support systems in the emergency department: opportunities to improve triage accuracy," *Journal of emergency nursing*, vol. 45, no. 2, pp. 220-222, Mar.2019. Doi: 10.1016/j.jen.2018.12.016.
- [44] M. Fernandes, S. M. Vieira, F. Leite, C. Palos, S. Finkelstein, and J. M. Sousa, "Clinical decision support systems for triage in the emergency department using intelligent systems: a review," *Artificial Intelligence in Medicine*, vol. 102, p. 101762, Jan.2020. Doi: 10.1016/j.artmed.2019.101762.
- [45] M. Knop, S. Weber, M. Mueller, and B. Niehaves, "Human factors and technological characteristics influencing the interaction of medical professionals with artificial intelligence–enabled clinical decision support systems: literature review," *JMIR Human Factors*, vol. 9, no. 1, p. e28639, Jan.2022. Doi: 10.2196/28639.
- [46] E. Wang, B. R. Brenn, and C. T. Matava, "State of the art in clinical decision support applications in pediatric perioperative medicine," *Current Opinion in Anesthesiology*, vol. 33, no. 3, pp. 388-394,Jun.2020. Doi: 10.1097/ACO.00000000000850.
- [47] Y. Kim, C. Groombridge, L. Romero, S. Clare, and M. C. Fitzgerald, "Decision support capabilities of telemedicine in emergency prehospital care: systematic review," *Journal of Medical Internet Research*, vol. 22, no. 12, p. e18959, Dec.2020, Doi: 10.2196/18959.
- [48] A. Kouri, J. Yamada, J. Lam Shin Cheung, S. Van de Velde, and S. Gupta, "Do providers use computerized clinical decision support systems? A systematic review and meta-regression of clinical decision support uptake," *Implementation Science*, vol. 17, no. 1, p. 21, Mar.2022. Doi: 10.1186/s13012-022-01199-3.
- [49] J. R. Marin et al., "Association of clinical guidelines and decision support with computed

tomography use in pediatric mild traumatic brain injury," *The Journal of Pediatrics*, vol. 235, pp. 178-183. e1, Aug.2021. Doi: 10.1016/j.jpeds.2021.04.026.

- [50] H. A. Watson, R. M. Tribe, and A. H. Shennan, "The role of medical smartphone apps in clinical decision-support: A literature review," *Artificial Intelligence in Medicine*, vol. 100, p. 101707, Sep.2019. Doi: 10.1016/j.artmed.2019.101707.
- [51] S. Simpson *et al.*, "Point-of-care creatinine to assist clinical decision making in suspected sepsis in the community," *Point of Care*, vol. 18, no. 2, pp. 41-45, Jun.2019. doi:10.1097/POC.00000000000184.
- [52] A. R. Mahmood and S. M. Hameed, "Review of Smishing Detection Via Machine Learning," *Iraqi J Sci*, vol. 64, no. 8, pp. 4244–4259, Aug. 2023. Doi: doi.org/10.24996/ijs.2023.64.8.42.
- [53] K. Hillson, J. Kantor, M. V. Pinto, A. J. Pollard, D. Kelly, and S. Vanderslott, "Motivations for paediatric vaccine trial participation," *Trials*, vol. 24, no. 1, Sep. 2023, Doi: 10.1186/s13063-023-07597-2.
- [54] N. E. Dean and I. M. Longini, "The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks," *Clinical Trials*, vol. 19, no. 4, pp. 402–406, Jan. 2022, Doi: 10.1177/17407745211073594.
- [55] D. Curran *et al.*, "Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals," *Journal of the American Geriatrics Society*, vol. 69, no. 3, pp. 744–752, Nov. 2020, Doi: 10.1111/jgs.16917.
- [56] S. Ilyas and P. H. Chandrasekar, "Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine," *Open Forum Infectious Diseases*, vol. 7, no. 7, Jul. 2020, Doi: 10.1093/ofid/ofaa274.
- [57] D. Singer, A. Salem, N. Stempniewicz, S. Ma, S. Poston, and D. Curran, "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50–59 years," *Vaccine*, vol. 41, no. 37, pp. 5360–5367, Aug. 2023, Doi: 10.1016/j.vaccine.2023.07.025.
- [58] R. Zeevaert, N. Thiry, C. Maertens de Noordhout, and D. Roberfroid, "Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis," *Vaccine: X*, vol. 15, p. 100397, Dec. 2023, Doi: 10.1016/j.jvacx.2023.100397.
- [59] J. Ahn, M. Kim, C. W. Won, and Y. Park, "Association between fish intake and prevalence of frailty in community-dwelling older adults after 4-year follow-up: the Korean frailty and aging cohort study," *Frontiers in Nutrition*, vol. 10, Aug. 2023, Doi: 10.3389/fnut.2023.1247594.
- [60] X. Song, B. Greeley, H. Low, J. Hoang, R. Kelly, and R. McDermid, "Deficit accumulation in relation to dementia and survival outcomes in residential care older adults," *Alzheimer's & Dementia*, vol. 19, no. S22, Dec. 2023, Doi: 10.1002/alz.071052.
- [61] J. D. Brown, G. Alipour-Haris, M. Pahor, and T. M. Manini, "Association between a Deficit Accumulation Frailty Index and Mobility Outcomes in Older Adults: Secondary Analysis of the Lifestyle Interventions and Independence for Elders (LIFE) Study," *Journal of Clinical Medicine*, vol. 9, no. 11, p. 3757, Nov. 2020, Doi: 10.3390/jcm9113757.
- [62] M. Kim and J. Kim, "The effects of social frailty on physical and psychological frailty among Korean older adults: A 10-year follow-up," *Korean Association of Health and Medical Sociology*, vol. 53, pp. 5–30, Apr. 2020, Doi: 10.37243/kahms.2020.53.5.
- [63] S. Pengpid and K. Peltzer, "Prevalence and Associated Factors of Frailty in Community-Dwelling Older Adults in Indonesia, 2014–2015," *International Journal of Environmental Research and Public Health*, vol. 17, no. 1, p. 10, Dec. 2019, Doi: 10.3390/ijerph17010010.
- [64] M. Almada, P. Brochado, and D. Portela, "Prevalence of falls and associated factors among community-dwelling older adults: a cross-sectional study," *Journal of Frailty & Aging*, pp. 1–7, 2020, Doi: 10.14283/jfa.2020.44.
- [65] T.-L. To, T.-N. Doan, W.-C. Ho, and W.-C. Liao, "Prevalence of Frailty among Community-Dwelling Older Adults in Asian Countries: A Systematic Review and Meta-Analysis," *Healthcare*, vol. 10, no. 5, p. 895, May 2022, Doi: 10.3390/healthcare10050895.